Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

38.59 -1.19 (-2.98%)

Streaming Delayed Price Updated: 1:51 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal ↗

Today 14:03 EDT

Via MarketBeat

Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss ↗

Today 13:52 EDT

As per the CEO, the company will have four late-stage trials by the end of 2026.

Via Stocktwits

2 Healthcare Stocks That Are Too Cheap to Ignore ↗

Today 12:43 EDT

These companies' shares have fallen too far, offering investors an attractive opportunity.

Via The Motley Fool

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

Today 10:08 EDT

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering...

Via Finterra

Disrupting the Pharmacy: A Deep-Dive into Hims & Hers Health (HIMS) in 2026

Today 9:39 EDT

As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a...

Via Finterra

Topics Artificial Intelligence Economy

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗

Today 9:01 EDT

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

Via Stocktwits

Topics Intellectual Property Lawsuit

HIMS Stock Rockets To Best Day Ever After Novo Nordisk Pact — Wall Street Upgrades Roll In As Shorts Lose $546M In One Day ↗

Today 0:25 EDT

Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners.

Via Stocktwits

Topics Intellectual Property Lawsuit

Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? ↗

March 09, 2026

Hims & Hers stock traded more than 40% higher after the deal was announced.

Via The Motley Fool

Topics Lawsuit

Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock ↗

March 09, 2026

The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.

Via The Motley Fool

Hims & Hers Stock Pops 40%: Everything You Need to Know ↗

March 09, 2026

Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.

Via The Motley Fool

Topics Lawsuit

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗

March 09, 2026

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

Via Stocktwits

Topics Intellectual Property Lawsuit

HIMS Stock Could Rally Up To 60% This Week? Fund Manager Says He Wouldn’t Be ‘Surprised’ As Novo Nordisk Patch-Up Buzz Grows ↗

March 09, 2026

Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs.

Via Stocktwits

Topics Intellectual Property Lawsuit

Better Weight Loss Stock: Novo Nordisk Vs. Amgen ↗

March 08, 2026

They may appeal to different kinds of investors.

Via The Motley Fool

2 Underrated Weight Loss Stocks to Buy Now ↗

March 08, 2026

These companies have a lot more to offer than their prospects in the weight loss market.

Via The Motley Fool

Topics Intellectual Property

Can This Next-Gen Obesity Drug Save Novo Nordisk? ↗

March 07, 2026

Things can't get that much worse for the drugmaker.

Via The Motley Fool

Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report ↗

March 07, 2026

According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare.

Via Stocktwits

Topics Initial Public Offering Intellectual Property Lawsuit

Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market? ↗

March 06, 2026

Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility.

Via The Motley Fool

Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors ↗

March 05, 2026

Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations.

Via The Motley Fool

The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes

March 04, 2026

NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a...

Via MarketMinute

Topics Economy Intellectual Property Lawsuit

Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again ↗

March 04, 2026

The notice comes weeks after a similar warning over Wegovy advertising, as the FDA ramps up scrutiny of marketing tied to GLP-1 drugs.

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

March 03, 2026

From Pomerantz LLP

Via GlobeNewswire

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

March 03, 2026

Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs.

Via The Motley Fool

Topics Intellectual Property

Unexpected Stock Picks and Looking to the Future ↗

March 02, 2026

Why does the shortest month of the year sometimes feel like the longest?

Via The Motley Fool

Why I'm Not Worried About Novo Nordisk Stock ↗

March 02, 2026

The stock is down big of late, but the business is by no means doomed.

Via The Motley Fool

Topics Intellectual Property

MarketBeat Week in Review – 02/23 - 02/27 ↗

February 28, 2026

Sometimes the best offense is a good defense. That’s what investors seem to be feeling. Technology stocks continue to be under pressure, and that money is flowing into traditionally defensive assets...

Via MarketBeat

The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials

February 27, 2026

The final trading week of February 2026 has laid bare a striking fracture in the U.S. equity markets. While the technology sector continues to feast on a relentless AI-driven "execution" cycle, the...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

Via MarketMinute

Topics Artificial Intelligence ETFs

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Via Finterra

Topics Economy Intellectual Property

Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗

February 27, 2026

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.

Via The Motley Fool

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The maker of Wegovy hasn't said its last words just yet.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.